Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial (Q34748493)

4 August 2017

title

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial (English)

1 reference

4 August 2017

0 references

Rosenbaum JF

1

1 reference

4 August 2017

Fava M

2

1 reference

4 August 2017

Hoog SL

3

1 reference

4 August 2017

Ascroft RC

4

1 reference

4 August 2017

Krebs WB

5

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

4 August 2017

published in

Biological Psychiatry

1 reference

4 August 2017

volume

44

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

77-87

1 reference

Physical symptoms associated with paroxetine discontinuation

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Patient compliance and medication perception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Antidepressant withdrawal: prospective findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Serotonin reuptake inhibitor withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Antidepressant withdrawal symptoms treated with anticholinergic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

7 January 2021

Fluoxetine withdrawal?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Withdrawal syndromes after paroxetine and sertraline discontinuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

A rating scale for depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Paroxetine induced withdrawal effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Potential withdrawal syndrome associated with SSRI discontinuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Discontinuation reactions following sertraline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Is there a serotonergic withdrawal syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

A New Depression Scale Designed to be Sensitive to Change

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Anticholinergic activity of imipramine and some analogs at muscarinic receptors of cultured mouse neuroblastoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Extrapyramidal symptoms upon discontinuation of fluoxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Clinical pharmacokinetics of selective serotonin reuptake inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Antidepressant withdrawal syndromes: phenomenology and pathophysiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Paroxetine withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2898%2900126-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(98)00126-7

1 reference

4 August 2017

1 reference